Status:
UNKNOWN
Graz Study on the Risk of Atrial Fibrillation
Lead Sponsor:
Medical University of Graz
Collaborating Sponsors:
Medtronic
Conditions:
Atrial Fibrillation
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient characteristics incre...
Eligibility Criteria
Inclusion
- CHA2DS2-VASc risk score \>= 4\*
- 18 years or older
Exclusion
- known history of atrial fibrillation
- implanted rhythm device
- pre-existing indication for oral anticoagulation
- (\*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age \>= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease (1 point); A - age \>=65 and \< 75 years (1 point); Sc - sex category (female) (1 point) ;
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT01461434
Start Date
November 1 2011
End Date
January 1 2016
Last Update
December 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LKH/Uniklinikum - Klinische Abteilung für Kardiologie
Graz, Austria, 8036